Shanghai Haimikang raises tens of millions of yuan for brain-computer interfaces
What's the deal? Shanghai Haimikang Intelligent Medical TechnologyDealroom has a profile for this one. Try Dealroom → has raised tens of millions of yuan in an early-stage round, the company announced in October 2026. The financing came from Shanghai Technology Innovation GroupDealroom has a profile for this one. Try Dealroom →'s Ceyuan Fund, backed by Shanghai's state investment arm.
What's the endgame? Haimikang develops brain-computer interfaces and exoskeletons for rehabilitation, applying artificial intelligence, sensors, and nano-fabrication to medical care. It is building what it calls an AI neural interface platform alongside implantable brain-machine interface products.
Where the money goes: The company will fund platform upgrades, implantable product development, medical-device clinical registration, market expansion, and further research. The aim is to strengthen its position in brain-computer interfaces and neuromodulation.
Why now? A single state-linked fund led the round, signalling institutional interest in China's neurotech sector. Clinical registration is a notable near-term priority, pointing to a push toward commercial medical use.
The signal: Brain-computer interfaces have moved from research labs toward clinical products, and Haimikang's backing from a government-affiliated fund shows where that capital is now flowing.
Read more: itjuzi.com
Image credit: uwnews
